Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4334 and Nicotine Biomarker Study in Schizophrenia
NCT05136690Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BNC375 in schizophrenia (2 arms), sponsored by Merck & Co. Primary endpoint: Mean Inter-trial Coherence (ITC) Magnitude of 40 Hz-derived Auditory Steady-state Response. Started Apr 2022; status: completed.
02
Drugs
BNC375
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05136690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136690.